Correction: Navamedic publishes a supplement to the offer document regarding the cash offer to the shareholders of Sensidose Aktiebolag

Press release

24 April 2023

Navamedic ASA published a press release on 24 April 2023 21:30 p.m. (CEST). The following is a correction of that press release. The correction refers to the removal of the word "recommended" in the title. The corrected press release is reproduced in its entirety below.

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or USA, or in any other jurisdiction where such offer pursuant to legislation, restrictions and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled "Important information" at the end of this announcement and in the offer document which has been published on Navamedic's website (https://navamedic.com/investors/stock-exchange-news/offer-for-sensidose/).

Navamedic publishes a supplement to the offer document regarding the cash offer to the shareholders of Sensidose Aktiebolag

On 29 March 2023, Navamedic ASA[1] ("Navamedic") announced a public offer to the shareholders of Sensidose Aktiebolag ("Sensidose") to tender all shares in Sensidose to Navamedic at a price of SEK 6.27 in cash per share (the "Offer"). An offer document was published on the same day, on 29 March 2023 (the "Offer document").

On 20 April 2023, the board of directors of Sensidose issued a statement regarding EQL Pharma AB's public offer, withdrawing the previously issued recommendation of the Offer. On 22 April 2023, it was announced that Navamedic has entered into agreements to acquire approximately 56.7 per cent of the shares in Sensdiose and that Navamedic has resolved to increase the consideration in the Offer to the shareholders of Sensidose to SEK 8 per share (the "Revised Offer"). Furthermore, Navamedic resolved to waive all of the conditions in the Offer, declare the Offer unconditional, and complete the acquisition of the shares tendered in the Offer. On 24 April 2023, the board of directors of Sensidose issued a statement regarding the Revised Offer.

On account of the above, Navamedic has prepared a supplement to the Offer document (the "Supplement"), in which the abovementioned documents are included in their entirety. Today, the Supplement has been published and is available at Navamedic's website (www.navamedic.com/investors/stock-exchange-news/offer-for-sensidose/) as well as Carnegie Investment Bank AB's website (www.carnegie.se), together with the Offer document and the acceptance form.

The supplement shall, at all times, be read together with, and forms an integrated part of, the Offer document published on 29 March 2023.

Information about the Offer and the Revised Offer

Information about the Offer and the Revised Offer is available at www.navamedic.com/investors/stock-exchange-news/offer-for-sensidose/

For additional information, please contact:

Lars Hjarrand, CFO of Navamedic

Mobile: +47 (0)917 62 842

E-mail: lars.hjarrand@navamedic.com

For administrative questions regarding the Offer and the Revised Offer, please contact your bank or the nominee registered as holder of your shares.

The information in this press release was submitted for publication by Navamedic in accordance with the Takeover rules for certain trading platforms. The information was submitted for publication on 24 April 2023 at 22:45 p.m. (CEST).

Important information

This press release has been published in Swedish and English. In the event of any discrepancy in content between the two language versions, the Swedish version shall prevail.

The Offer is not being made, directly or indirectly, in or into Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or USA, or in any other jurisdiction where such offer pursuant to laws, restrictions or regulations in such relevant jurisdiction would be prohibited pursuant to applicable law, by use of mail or any other communication means or instrumentality (including, without limitation, facsimile transmission, electronic mail, telex, telephone and the Internet) of interstate or foreign commerce, or of any facility of national securities exchange or other trading venue, of Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or USA, or in any other jurisdiction where such offer pursuant to laws, restrictions or regulations in such relevant jurisdiction would be prohibited pursuant to applicable law, and the Offer cannot be accepted by any such use or by such means, instrumentality or facility of, in or from, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or USA, or in any other jurisdiction where such offer pursuant to laws, restrictions or regulations in such relevant jurisdiction would be prohibited pursuant to applicable law. Accordingly, this press release or any other documentation relating to the Offer are not being and should not be sent, mailed or otherwise distributed or forwarded in or into Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or USA, or in any other jurisdiction where such offer pursuant to laws, restrictions or regulations in such relevant jurisdiction would be prohibited pursuant to applicable law.

This press release is not being, and must not be, sent to shareholders with registered addresses in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or USA. Banks, brokers, dealers and other nominees holding shares for persons in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or USA, must not forward this press release or any other document received in connection with the Offer to such persons.

Statements in this press release relating to future status or circumstances, including statements regarding future performance, growth and other trend projections and other benefits of the Offer, are forward-looking statements. These statements may generally, but not always, be identified by the use of words such as "anticipates", "intends", "expects", "believes", or similar expressions. By their nature, forward-looking statements involve risks and uncertainty since they relate to events and depend on circumstances that occur in the future. There can be no assurance that actual results will not differ materially from those expressed or implied by these forward-looking statements due to many factors, many of which are outside the control of Navamedic and Sensidose. Any such forward-looking statements speak only as of the date on which they are made and Navamedic has no obligation (and undertakes no such obligation) to update or revise any of them, whether as a result of new information, future events or otherwise, except for in accordance with applicable laws and regulations. However, the reader is advised to take part of any additional statements that Navamedic or Sensidose have made or may make in the future.

Carnegie AS is not responsible to anyone other than Navamedic for advice in connection with the Offer.